阿得拉尔
 |
 | |
 | |
| 组成 | |
|---|---|
| amphetamine aspartate monohydrate | 25% – 中樞神經刺激劑 (12.5% levo; 12.5% dextro) |
| amphetamine sulfate | 25% – 中樞神經刺激劑 (12.5% levo; 12.5% dextro) |
| dextroamphetamine saccharate | 25% – 中樞神經刺激劑 (0% levo; 25% dextro) |
| dextroamphetamine sulfate | 25% – 中樞神經刺激劑 (0% levo; 25% dextro) |
| 臨床資料 | |
| 商品名 | Adderall, Adderall XR, Mydayis |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a601234 |
| 核准狀況 | |
| 依賴性 | 生理: 無[1] 心理: 中等[2] |
| 成癮性 | 中等 |
| 给药途径 | 口服、噴射、栓剂、口腔黏膜吸收 |
| ATC碼 | |
| 法律規範狀態 | |
| 法律規範 |
|
| 识别信息 | |
| CAS号 | 300-62-9  51-64-9 |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
阿得拉尔或阿得拉（英語：Adderall、Adderall XR、Mydayis）是一种复方药，包含中樞神經系統兴奋剂苯丙胺的两种对映异构体的四种盐类。阿得拉尔主要用于治疗注意力不足過動症（ADHD）和發作性嗜睡病，也有人用它作运动员兴奋剂和益智药，以及享乐时用作春药和欣快剂。
文獻來源
- ^ Malenka RC, Nestler EJ, Hyman SE. Chapter 15: Reinforcement and Addictive Disorders. Sydor A, Brown RY (编). Molecular Neuropharmacology: A Foundation for Clinical Neuroscience 2nd. New York: McGraw-Hill Medical. 2009: 367. ISBN 9780071481274.
While physical dependence and withdrawal occur with some drugs of abuse (opiates, ethanol), these phenomena are not useful in the diagnosis of addiction because they do not occur with other drugs of abuse (cocaine, amphetamine) and can occur with many drugs that are not abused (propranolol, clonidine).
- ^ Stahl SM (March 2017). "Amphetamine (D,L)". Prescriber's Guide: Stahl's Essential Psychopharmacology (6th ed.). Cambridge, United Kingdom: Cambridge University Press. pp. 45–51. ISBN 9781108228749. Retrieved 5 August 2017.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||